Heightened anticipation for Trodelvy readout as Gilead builds sales staff

Gilead is tripling its U.S. sales force for Trodelvy ahead of a key readout for the ADC in a subset of breast cancer patients, with a new timeline that the company expects will deliver simultaneous readouts measuring progression-free and overall survival.

In its 4Q21 and full-year earnings report late Tuesday, Gilead Sciences Inc. (NASDAQ:GILD) CMO Merdad Parsey said the company now expects the PFS and OS readouts from the Phase III TROPiCS-02 study of Trodelvy sacituzumab govitecan-hziy to occur in March, due to a “convergence of events.” Buysiders told BioCentury last month that they were watching TROPiCS-02 closely, as it could lead to a major label expansion for the drug; the prior timeline had called for the primary PFS readout in January or February...